Merit Medical projects $7 million in U.S. revenues for its Rhapsody product in 2026, based on unit-volume and ASP assumptions inferred from market data and management commentary. This guidance reflects modest market penetration primarily in the non-hospital setting.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Please provide the unit-volume and ASP assumptions underlying the $7M Rhapsody 2026 guide.
Analysis of Unit-Volume and Average Selling Price (ASP) Assumptions Behind the $7M Rhapsody 2026 Revenue Guidance
Merit Medical Systems, Inc. projects approximately $7 million in U.S. revenues from its Rhapsody Chronic Ischemic Event (CIE) product for fiscal year 2026, roughly doubling from $3 million in 2025. The company has provided some qualitative and contextual details that can help infer the underlying assumptions on units and ASP but has explicitly declined to disclose precise assumptions on unit volumes or site of care pricing. Here is a detailed synthesis based on management commentary and market data:
Using the market data, a rough modeling approach can be made:
| Assumption | Value | Source/Comment |
|---|---|---|
| Total nonhospital procedures | 60,000 - 70,000 | Clarivate data 12 |
| Approximate stents per procedure | 1.2 | Clarivate data 12 |
| Total potential stents in nonhospital setting | 72,000 - 84,000 | 60k-70k procedures × 1.2 stents |
| ASP for covered stents (nonhospital) | ~$2,400 | Clarivate data 12 |
| Implied market penetration for $7M revenue | ~2.5% - 3% | $7M ÷ ($2,400 × 84,000) ≈ 3.5%; management states low to mid-single digits 2 |
This suggests Merit expects to capture about low-to-mid single-digit market share (approx. 2.5%–5%) of the covered stent procedures in the U.S. nonhospital setting by 2026 to reach $7 million in sales, assuming their pricing is in the ballpark of the reported ASP (~$2,400 per stent).
Merit’s reluctance to disclose exact unit or ASP assumptions is typical given competitive dynamics and evolving reimbursement landscapes. Nevertheless, the external market context and company commentary provide a credible framework for the $7 million estimate centered on modest penetration of the prevailing procedural volume and established ASP ranges.
References:
1 Clarivate data: 100,000 stents in 77,000 procedures, 1.2 stents/procedure, 60-70k nonhospital procedures (Excerpts 1,2)
2 $2,400 ASP for covered stents in nonhospital setting and low-to-mid-single-digit penetration implied for $7M guidance (Excerpts 1,2)
3 Early commercialization, confidence in product, conservative guidance for 2026 (Excerpts 1,3,7)
5 Sales approach focused on both hospital and nonhospital sites, administrative and reimbursement hurdles mentioned (Excerpt 8)
2 Contribution to revenue growth and Rhapsody positioning (Excerpt 2)
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
This analysis explores Merit Medical's strategic shift in revenue reporting, focusing on its implications for Q1 2026 performance and investor understanding.
Sources used
Research questionWhat are the implications of Merit Medical's revenue reclassification strategy for Q1 2026?
Answer outline
Micron said its overall SCA pricing framework remained broadly similar, while newer negotiations reflected current market pricing and expected future tightness. Around three-quarters of SCA revenue had defined pricing frameworks; the remainder was subject to periodic negotiation or market-linked pricing. Management did not indicate that all existing price floors and ceilings had reset to current levels.
Sources used
Research questionWhat did management say about SCA pricing aligned with market conditions?
Micron’s stronger demand visibility, including continued server growth and agentic AI, has extended customer allocation discussions into 2028. Meanwhile, HBM’s growing share of production, technology-transition limits, and slow capacity ramp-ups constrain supply. These conditions support strong margins into 2028, but Micron has not forecast that margins will exceed the level expected for 2027.
Sources used
Research questionWhat changed in Micron’s outlook to make supply-demand conditions appear tighter in 2028 than in 2026 and 2027, and what does that imply for 2028 margins relative to the expected 2027 level?
Answer outline
Broadcom outlines a 2027–2028 gigawatt roadmap totaling about 30 GW, with AI semiconductor revenue of roughly $115B in 2027 and $230B in 2028. The implied revenue per roadmap GW is about $11.5B, while deployed content per GW remains in the $20–$30B range, signaling growth from higher gigawatt volumes as XPUs evolve.
Sources used
Research questionCan you confirm the 2027–2028 gigawatt projections and discuss the implied revenue per gigawatt and its trend as XPUs evolve?
Answer outline
International growth remained broad-based and resilient amid regional conflicts, with limited near-term impact and a positive, backlog-supported outlook that could soften if conditions persist.
Sources used
Research questionWhat did management say about International growth amid regional conflicts?
Answer outline
Marsh's Q2 2026 results show pricing headwinds concentrated in property-catastrophe reinsurance, but RIS is offset by robust Marsh Risk growth, broad new-business momentum, and capacity investments in hiring. Management emphasizes capacity-building and diverse risk solutions as key to sustaining organic growth near last year's levels, supported by international expansion, specialty expansion, and demand for complex risk financing despite softer rates.
Sources used
Research questionHow do you reconcile pricing headwinds in Risk & Insurance Services with hires and new business as you guide to organic revenue growth similar to last year?
Answer outline
Best Buy enters August with modest momentum and near-term tailwinds from back-to-school promotions and seasonal demand. Computing demand appears hybrid—driven by replacement and innovation rather than a solely AI-driven cycle, with no material evidence of Apple pull-forward.
Sources used
Research questionFor August and beyond, is there a back-half tailwind, and how is computing demand split between replacement versus AI cycle, and is there evidence of demand pull-forward from Apple's price increases?
Answer outline
Agilent's Q3 2026 results show China driving 9% growth outside A&G, led by double-digit pharma and biotech demand and mid-teens food testing, with CAM strength supporting the broader mix. Stimulus impact is minimal to date, and management guides continued momentum into year-end, upgrading to high-single-digit growth, though sustainability remains a watch point.
Sources used
Research questionWhat drove China growth outside of A&G, and what's the mix across pharma, food, biotech; how sustainable is the 9% growth in China vs the rest?
Answer outline
Walmart’s management frames payback from price investments and rollbacks around durable customer outcomes and market-share gains, not immediate offsets. They note a lag between price actions and benefits, emphasize tracking unit movement and category effects, and indicate that their goal is for rollbacks to become permanent price increases where feasible, while maintaining rigorous discipline on returns.
Sources used
Research questionWhat did management say about Payback on price investments and rollbacks?
Answer outline
ADI outlines a multi-factor path to 20%+ revenue growth into fiscal 2027, anchored by secular AI/data-center momentum, cyclical demand normalization, and pricing tailwinds. The company notes capacity is being scaled and margins are broadly supported amid growth investments.
Sources used
Research questionWhat mix of secular, cyclical, and pricing factors underpins potential 20%+ revenue growth into fiscal 2027, and are there capacity or operating leverage constraints?
Answer outline
NOV outlines a 2H Middle East recovery with a roughly 10%-15% sequential uptick from Q2 to Q3, tempered by ongoing logistics constraints. It also notes no explicit Q4 top-line YoY target, presenting a scenario-based EBITDA sensitivity of $20–$25 million if the improvement falters.
Sources used
Research questionWhat are NOV's expectations for Middle East trends in the second half of the year and the potential fourth-quarter top-line impact given the current uncertainty?
Answer outline
Royal Caribbean asserts its Caribbean pricing power remains intact despite rising promotions, supported by differentiated demand, loyalty, and guest experiences. The quarter showed yields in the Caribbean running about 100 basis points above guidance, signaling stronger close-in demand, while European headwinds constrained 2026 yield prospects. Consequently, management reaffirmed a 2026 yield range of 1.75%-2.25%, noting the upside would have been higher without geopolitical impacts in Europe.
Sources used
Research questionHas the uptick in Caribbean promotions impacted your ability to raise prices there, and would you have raised your 2026 yield guidance absent European headwinds?
Answer outline
Dafinchi